Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1289-2 is a small, noncoding RNA molecule that regulates gene expression by binding to complementary sequences within target mRNAs, resulting in their silencing or degradation. In human cancer biology, particularly oral squamous cell carcinoma, miR-1289-2 exhibits strong tumor suppressor functionality: its expression is reduced in malignant tissue, and restoration via synthetic mimics significantly inhibits tumor cell proliferation both in vitro and in animal models. miR-1289-2 directly targets key genes involved in cell growth and survival, with magnesium transporter 1 (MAGT1) being a principal functional target in OSCC. Early-stage therapeutic research positions miR-1289-2 as a promising molecular target for RNA-based or gene therapy approaches, pending further validation in broader cancer types and clinical studies[1][2].
Synthetic mimic substituting or restoring endogenous miR-1289 reduces tumor cell growth and represses target gene expression, notably magnesium transporter 1 (MAGT1)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1289-2 (miR-1289-2).